FDA Approves Leqembi Iqlik (lecanemab) for Alzheimer's DiseaseFDA approves new Alzheimer's drug Leqembi Iqlik with flexible dosing options.

FDA Published July 15, 2026 DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note: Confirm amyloid beta pathology and obtain baseline MRI before initiating Leqembi; monitor for ARIA with scheduled MRIs.

The FDA has approved Leqembi Iqlik (lecanemab) for the treatment of Alzheimer's disease. The amyloid beta-directed antibody is indicated for patients with mild cognitive impairment or mild dementia stage of disease, the population studied in clinical trials. Clinicians should confirm amyloid beta pathology before initiating therapy and obtain a baseline brain MRI. The approval provides both intravenous and subcutaneous maintenance dosing options after an initial 18-month intravenous starting regimen. This new formulation offers flexibility in administration routes for patients and providers.

＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)

Mechanism of Action

Leqembi is an amyloid beta-directed antibody. It binds to soluble amyloid beta aggregates and reduces amyloid beta plaques in the brain.

Indication & Patient Population

Leqembi is indicated for the treatment of Alzheimer's disease. Treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Dosing & Administration

Confirm the presence of amyloid beta pathology prior to initiating treatment. Obtain a recent baseline brain MRI prior to initiating treatment. The recommended starting dosage is 10 mg/kg once every 2 weeks administered as an intravenous infusion over approximately one hour. After 18 months, continue treatment once every 2 weeks or transition to maintenance dosage: intravenous 10 mg/kg once every 4 weeks or subcutaneous 360 mg once a week using the Leqembi Iqlik autoinjector. Obtain MRI prior to the 3rd, 5th, 7th, and 14th infusions. Dosing interruptions are recommended for ARIA based on type, severity, and symptoms.

Key Clinical Trial Data

Trial data not available in label.

Warnings & Contraindications

Leqembi can cause amyloid related imaging abnormalities -edema (ARIA-E) and -hemosiderin deposition (ARIA-H). Monitoring for ARIA with MRI is required. Dosing interruption recommendations are provided based on ARIA severity and symptoms. In patients who develop intracerebral hemorrhage, specific guidance is provided.

Place in Therapy

Leqembi is an amyloid beta-directed antibody for Alzheimer's disease. It is indicated for patients with mild cognitive impairment or mild dementia. The availability of both intravenous and subcutaneous maintenance dosing provides flexibility. Clinicians should weigh the benefits against the risks of ARIA and the need for regular MRI monitoring.

The FDA has approved a new drug called Leqembi Iqlik (lecanemab) for treating Alzheimer's disease. This medicine is a type of antibody that targets amyloid beta plaques in the brain, which are linked to Alzheimer's. It is specifically for people in the early stages of the disease, such as those with mild cognitive impairment or mild dementia. Before starting treatment, doctors must confirm the presence of amyloid plaques and do a baseline brain MRI to check for safety.

What makes this approval different is that after an initial 18 month course of intravenous (IV) infusions, patients can switch to a maintenance dose given either as an IV infusion or as a subcutaneous injection under the skin. This gives patients and their doctors more flexibility in how the drug is given. The approval is based on clinical trials that showed the drug can slow the progression of Alzheimer's symptoms, but it is not a cure.

It is important to know that this drug works best in early stages of Alzheimer's. It may not help people with more advanced disease. Also, like all medicines, it can have side effects, including brain swelling or small bleeds, which is why monitoring with MRI is needed.

If you or a loved one has Alzheimer's, talk to your doctor about whether Leqembi Iqlik might be right for you. Your doctor can help you understand the benefits and risks based on your specific health situation.

What this means for you:

Leqembi Iqlik is a new option for early Alzheimer's that can slow symptoms, but it is not a cure.

Study Details

Study typeFda approval

PublishedAug 2025

View Original Abstract ↓

1 INDICATIONS AND USAGE LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. LEQEMBI is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. ( 1 )

FDA Approves Leqembi Iqlik (lecanemab) for Alzheimer's DiseaseFDA approves new Alzheimer's drug Leqembi Iqlik with flexible dosing options.

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

FDA Approves Leqembi Iqlik (lecanemab) for Alzheimer's DiseaseFDA approves new Alzheimer's drug Leqembi Iqlik with flexible dosing options.

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

Related in Neurology

From Other Specialties